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A 24-year-old male developed bulbar palsy, ophthalmoplegia, ptosis, and shoulder weakness bilaterally 2 weeks 
after he had experienced an upper respiratory infection. The electrodiagnostic study demonstrated axonal 
polyradiculoneuropathy. The repetitive nerve stimulation study (RNS) showed no significant decrement of the 
compound muscle action potentials (CMAPs). The videofluoroscopic swallowing study (VFSS) showed severe 
impairment of the pharyngeal phase of swallowing. He was diagnosed as having the pharyngeal-cervical-brachial 
variant of Guillain-Barré syndrome. The patient’s dysphagia was not improved for 3 months. A follow up RNS 
showed a signifi  cant decrement of the CMAPs. Pyridostigmine bromide was tried to improve the dysphagia. Th  e 
patient showed immediate improvement of his dysphagia on the VFSS after the trial with pyridostigmine bromide. 
Pyridostigmine bromide was given before each meal for 8 days and he showed continuous improvement of his 
dysphagia. Th   e follow up VFSS after 3 months showed complete recovery of dysphagia.
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INTRODUCTION
Th   e pharyngeal-cervical-brachial (PCB) variant of Guil-
lain-Barré syndrome (GBS) is very rare and is character-
ized by weakness of the pharyngeal, cervical, and brachi-
al muscles.
1 Th   e prognosis of this variant generally shows 
a slow and incomplete recovery over several months.
2,3 It 
has been reported that the ptosis associated with the PCB 
variant is slightly improved by administration of neostig-
mine or edrophonium, but the other symptoms are not 
improved.
3 We treated severe dysphagia in a patient suf-
fering with the PCB variant by administering pyridostig-
mine bromide. Here, we report on our case and provide a 
review of the relevant literature. 
CASE REPORT
A 24-year-old male patient developed whole body my-
algia, ptosis and neck muscle weakness (day 1) after ex-
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periencing 2 weeks of cough, rhinorrhea, mild fever, and 
sore throat. He took cold medicine, but developed dys-
phagia, dysarthria, and shoulder weakness bilaterally 4 
days later. On day 4, he was admitted to the Department 
of Neurology at the University Hospital. 
At the time of admission, he had ptosis, dysarthria, 
diplopia, dysphagia, facial palsy, ophthalmoplegia, and 
ataxia without hemisensory disturbance. His conscious-
ness was not impaired. Manual muscle testing revealed a 
-3/5 weakness in the cervical and shoulder muscles and 
a -4/5 weakness in the other muscles. The sensory test-
ing and the deep tendon reflexes showed normal find-
ings. Th   ere were no signs of meningeal irritation, and the 
brain magnetic resonance imaging (MRI) did not show 
any abnormal lesion. Laboratory test results such as anti-
acetylcholine receptor antibodies, creatine kinase, aspar-
tate aminotransferase, alanine aminotransferase, lactate 
dehydrogenase, and C-reactive protein were normal. Th  e 
cerebrospinal fluid study showed no signs of infection 
or albuminocytologic dissociation. No abnormalities of 
the thymus were shown on computed tomography. An 
electrodiagnostic study was performed on day 38. The 
repetitive nerve stimulation study (RNS) did not show a 
significant decrement of the compound muscle action 
potentials (CMAPs) in the abductor digiti minimi and 
orbicularis oculi muscles. The nerve conduction and F 
wave studies showed normal findings, but there were 
abnormal spontaneous activities at the muscles of all 
the extremities and this was compatible with the axonal 
polyradiculoneuropathy seen on the needle electromy-
ography.
Based on the symptoms and examinations, the patient 
was diagnosed as having GBS, and we started treatment 
with immunoglobulin. He was given 25,000 mg immuno-
globulin intravenously daily for 4 days. The ptosis, dip-
lopia, facial palsy, ophthalmoplegia, limb muscle weak-
ness, and ataxia were improved after immunoglobulin 
therapy and physical therapy, but the dysphagia was 
not improved. The videofluoroscopic swallowing study 
(VFSS) on day 40 showed severe dysfunctional oropha-
ryngeal transfer of the barium paste and subglottic aspi-
ration of the liquid barium due to the severe weakness 
and lack of coordination of the oropharyngeal muscles. 
Oromotor facilitation and electrical stimulation therapy 
to the pharyngeal muscles was done for the swallowing 
difficulty. The waveform, amplitude, duration, and fre-
Table 1. Results of Sensory Nerve Conduction Studies
Nerve Stimulation Recording DL (msec) Amplitude* (μV)
Median Wrist Second digit 2.80 80.8 
Ulnar Wrist Fifth digit 2.00 53.0 
Superfi  cial peroneal Lateral leg Foot 2.30 21.3 
Sural Calf Lateral malleolus 2.30 21.3 
DL: Distal latency (onset latency)
*Baseline to peak amplitude
Table 2. Results of Motor Nerve Conduction Studies
Nerve Stimulation Recording DL (msec) Amplitude* (mV) Velocity
† (m/s)
Median Wrist APB 3.70 6.9 
Elbow 6.8 57.1
Ulnar Wrist ADM 2.65 6.0 
Elbow 5.9 55.3
Common peroneal Ankle EDB 3.85 2.3 
Fibular head 2.3  50.4
Tibial Ankle AH 3.55 13.3 
Knee 10.6 53.4
APB: Abductor pollicis brevis, ADM: Abductor digit minimi, EDB: Extensor digitorum brevis, AH: Abductor hallucis, 
DL: Distal latency (onset latency)
*Baseline to peak amplitude, 
†Segmental nerve conduction velocity from the proximal site to the distal siteKwang Lae Lee, et al.
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quency of the electrical stimulator were rectangular sym-
metric biphasic, 7 mA, 300 msec, and 80 Hz, respectively. 
Th   e follow up VFSS on day 54 did not show improvement 
of the dysphagia. 
He was transferred to the Department of Rehabilitation 
Medicine for treatment of the dysphagia on day 61. At 
the time of transfer, he was being maintained on naso-
gastric tube feeding and complained of mild dysarthria. 
Th   e tongue muscles showed weakness and the soft palate 
movement was impaired. He had mild facial weakness. 
Manual muscle testing revealed 4/5 weakness in the 
shoulder and hip muscles bilaterally with normal muscle 
power in the other muscles. The signs and symptoms 
were persistent and they could not be improved by rest. 
Antibodies for CMV, EBV, and anti-GM1 IgG antibodies 
were detected in the serum on day 70. Anti-acetylcholine 
receptor antibodies were not detected. Th   e weakness of 
the shoulder and hip muscles was improved after inten-
sive rehabilitation, but the dysphagia persisted. A follow 
up electrodiagnostic study was performed on day 70. Th  e 
nerve conduction study on the right limbs showed nor-
mal sensory fiber conductions and normal motor fiber 
conduction velocities, but there was decreased ampli-
tude of the CMAPs (Table 1 and 2). Th   e F wave studies at 
the median, ulnar, common peroneal and tibial nerves 
showed normal findings. Needle electromyography 
showed abnormal spontaneous activities at the muscles 
of all the extremities and some evidence of partial axonal 
regeneration as compared to the previous study (Table 
3). RNS showed a signifi  cant decrement of the CMAPs at 
the orbicularis oculi muscle on 3 Hz repetitive simulation 
(Table 4). We interpreted that these fi  ndings of dysfunc-
tion of the conduction at the neuromuscular junction 
were caused by the axonal polyradiculoneuropathy, and 
decided to perform a pyridostigmine challenge test for 
the dysphagia to confi  rm this interpretation.
Th   e pyridostigmine challenge test was performed with 
VFSS on day 75. Before administering the pyridostigmine, 
fluoroscopic monitoring revealed pharyngeal retention 
and aspiration of barium coated food without any pas-
sage to the esophagus, which suggested no improve-
ment of the pharyngeal weakness. However, 30 minutes 
after oral administration of pyridostigmine (60 mg), the 
Table 3. Results of Needle Electromyography
Muscle (Right) ASA MUAP
APB/ADM/FDI Fib/PSW (+++) Long duration/polyphasic
FCR/FCU Fib/PSW (+++) Long duration/polyphasic
Biceps brachii Fib/PSW (+++) Long duration/polyphasic
Triceps Fib/PSW (+++) Long duration/polyphasic
Deltoid Fib/PSW (+++) Long duration/polyphasic
Cervical paraspinal Fib/PSW (+++) Long duration/polyphasic
Tibialis anterior Fib/PSW (+++) Long duration/polyphasic
Peroneus longus Fib/PSW (+++) Long duration/polyphasic
Gastrocnemius Fib/PSW (+++) Long duration/polyphasic
Vastus medialis Fib/PSW (+++) Long duration/polyphasic
TFL Fib/PSW (+++) Long duration/polyphasic
Lumbar paraspinal Fib/PSW (+++) Long duration/polyphasic
ASA: Abnormal spontaneous activities, MUAP: Motor unit action potentials, APB: Abductor pollicis brevis, ADM: 
Abductor digit minimi, FDI: First dorsal interosseous, FCR: Flexor carpi radialis, FCU: Flexor carpi ulnaris, TFL: Tensor 
fascia lata, Fib: Fibrillation potentials, PSW: Positive sharp waves
Table 4. Results of Repetitive Nerve Stimulation Study on 
the Right Orbicularis Oculi Muscle
Time
Amplitude* 
(mV)
Percentage
† 
(%)
Before exercise 0.5 5.8
Immediately after exercise 0.9 4.9
1 minute after exercise 0.9 11.6
10 minutes after exercise 0.6 4.7
*Amplitudes of the first compound muscle action 
potentials, 
†The percentages of amplitude decrements 
of the fifth compound muscle action potentials as 
compared to the fi  rst onesTreatment of Dysphagia with Pyridostigmine in Guillain-Barré Syndrome
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amount of retention significantly decreased and food 
passage to the esophagus was clearly seen (Fig. 1). With 
this finding we confirm the effect of pyridostigmine for 
the treatment of dysphagia in this case. Since this study, 
pyridostigmine bromide (60 mg) was regularly given to 
the patient 30 minutes before each meal time, and the 
patient could swallow a soft diet with some difficulty. 
Within several days of pyridostigmine administration, 
the swallowing diffi   culty was signifi  cantly improved and 
the nasogastric tube was removed. On day 83, the patient 
could eat a full oral diet without pyridostigmine. On day 
89, the follow up VFSS showed further improvement of 
the pharyngeal weakness and no aspiration of any mate-
rial. 
He was discharged on day 90. The follow up VFSS on 
day 173 showed full recovery from the pharyngeal weak-
ness and a normal swallowing function.
DISCUSSION
The PCB variant of GBS is diagnosed if the following 
conditions are satisfied; progressive severe weakness of 
the pharyngeal, cervical, and brachial muscles, and the 
absence or decrement of the deep tendon refl  exes of the 
arm in a week and 3 weeks, respectively, mild weakness 
of the lower extremities > grade 4/5, a past history of in-
fection in the 4 weeks before the neurologic presentation, 
albuminocytologic dissociation on the cerebrospinal 
fl  uid study, and electrophysiological abnormalities of the 
conduction velocities.
4 However, it is possible that nor-
mal or increased deep tendon reflexes can be seen and 
the cerebrospinal study is not able to show albuminocy-
tologic dissociation. It has been reported that electromy-
ography reveals only decrements of amplitudes on the 
CMAPs or even normal findings. Therefore, it is proper 
that a patient with GBS is diagnosed to have the PCB vari-
ant if he does not show a typical presentation, but rather 
the patient having the PCB variant shows unusual pre-
sentations such as weakness of the pharyngeal, cervical, 
and brachial muscles.
2,3
Th   e PCB variant must be distinguished from botulism, 
diphtheria infection, myasthenia gravis, and multiple 
sclerosis.
2,3 In our patient, we could exclude botulism and 
diphtheria infection according to the clinical fi  ndings and 
electrophysiological fi  ndings and there was no evidence 
of infection. We could rule out multiple sclerosis by the 
cerebrospinal fluid study, MRI, and electromyography. 
Th   e RNS done on day 70 showed a signifi  cant decrement 
of the CMAPs, but there were abnormal spontaneous ac-
tivities at all the muscles we examined and there was no 
evidence of fatigue by exercise. Th   e signs and symptoms 
of our patient were persistent and could not be improved 
by rest. Anti-acetylcholine receptor antibodies were not 
detected. An acetylcholine esterase inhibitor can im-
prove symptoms, but it does not affect the prognosis.
5 
Th   e patient took the medicine for only 8 days. If the dis-
ease was myasthenia gravis, the dysphagia would recur 
after the cessation of the medicine. Th   e RNS showed no 
decrement at the time of the symptoms of diplopia, pto-
sis, facial palsy, and ophthalmoplegia. On the basis of the 
above fi  ndings, we could rule out myasthenia gravis. Th  e 
decrement of CMAPs on the RNS can be explained by the 
exocytosis of insufficient acetylcholine at the immature 
nerve endings in the course of recovery from the periph-
eral neuropathy with axonal damage.
6 It is speculated 
that in our patient, the early RNS showed normal find-
ings, but later the RNS showed a significant decrement 
by dysfunction of the conduction at the neuromuscular 
junction developing during the course of recovery from 
the axonal peripheral neuropathy. We could diagnose 
Fig. 1. (A) Barium liquid did not 
transfer to the esophageal phase 
because of pharyngeal muscle weak-
ness. The image showed severe 
retention of material at the vallecula 
(white arrow) and the pyriform sinus 
(triangle). (B) The same material 
transferred to the esophageal phase 
30 minutes after taking pyridostig-
mine bromide.Kwang Lae Lee, et al.
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this case as the PCB variant of GBS according to the clini-
cal course and the laboratory fi  ndings.
GBS is a type of autoimmune disease and it is usually 
preceded by upper respiratory or gastrointestinal infec-
tion. On the basis of a recent study, infections by Campy-
lobacter jejuni, CMV, EBV and Mycoplasma pneumoniae 
appear to be the causes of GBS.
7 A definite mechanism 
has not been established, but it has been revealed that 
the antibodies generated by the activation of immune 
responses after these infections make a cross-bridge via 
molecular mimicry with antigens in the peripheral nerves 
and this destroys them.
7,8 Th   is hypothesis is supported by 
the fact that anti-ganglioside antibodies have been found 
in the serum of GBS patients. Th   ese antibodies assist in 
making the diagnosis.
7 In the PCB variant, serum anti-
GT1a IgG antibody is usually revealed because a GT1a 
ganglioside is abundantly detected at the cranial nerves 
such as the glossopharyngeal and vagus nerves. But other 
antibodies such as serum anti-GQ1b and anti-GM1 IgG 
are occasionally revealed.
9 Our patient showed 2 types 
of viral antibodies. Th   is result is thought to indicate that 
there was a co-infection or one infection after the other 
infection during his hospitalization. Yet this examination 
had a limitation as it checked only a IgG without IgM. 
There was definitely a viral infection in his recent past 
history and we can speculate that the formation of serum 
anti-GM1 IgG antibody affected the occurrence of dis-
ease. 
Pyridostigmine bromide is an acetylcholine esterase 
inhibitor used to treat myasthenia gravis. This medica-
tion delays the elimination of acetylcholine in the neu-
romuscular junction by inhibiting acetylcholine esterase 
and therefore activates neuromuscular transmission.
5 On 
the hypothesis that this medication could improve the 
dysphagia of our patient, who showed a signifi  cant dec-
rement of CMAPs on the RNS, we tried using it to treat his 
symptoms. His dysphagia had not been improved by >2 
months of occupational therapy. However, on day 75, the 
VFSS performed after taking the medication showed im-
provement of the dysphagia. We could rule out spontane-
ous recovery of dysphagia because the result was diff  er-
ent from that at 30 minutes before taking the medication. 
Although we don’t know whether only taking the medi-
cation changed the prognosis of the disease, we thought 
that the medication helped to improve the dysphagia and 
the patient, who previously could not swallow, became 
able to swallow. Swallowing training is generally the 
best therapy for swallowing disorders.
10 In conclusion, 
we think the medication helped the pharyngeal muscle 
to strongly contract due to the eff  ect on the delay of the 
elimination of acetylcholine in the neuromuscular junc-
tion and the more active dysphagia training through 
swallowing could have changed the prognosis of the dys-
phagia. Th   e limitation of our study is that follow up RNS 
should have been done after remission of the dysphagia 
to test whether the medication affected transmission at 
the neuromuscular junction and therefore improved the 
dysphagia, but this was not performed. We cannot com-
pletely rule out the possibility of a spontaneous recovery.
Our case indicates that dysphagia rehabilitation by ad-
ministering acetylcholine esterase inhibitor is possibly 
a sound method for treating the dysphagia in those GBS 
patients with a signifi  cant decrement of the CMAPs seen 
on a RNS. A study with a large population focusing on the 
mechanism of improvement and the possibility of using 
this treatment is needed in the future.
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